EN DE
Watch ConvaTec Group PLC for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

ConvaTec Group PLC (CTEC) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of ConvaTec Group PLC stock £1.56, price £2.68, that is 41.8% below the price, quality 68 out of 100. Rating: strongly overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB · ISIN GB00BD3VFW73

CG ConvaTec Group PLC logo Broad data Nov 18, 2026

ConvaTec Group PLC

CTEC · LSE

Far too expensive (fair value 42% below the price), but solid company and rising price: meets 2 of 3 rules.

Follow free in the weekly email
Quality 68/100 
Rising price (uptrend) 
Healthy Growth (revenue 5y +5.6 %/yr in USD) 
Generates free cash flow 
2.1% dividend yield · Sustainable
Recent news mostly positive 
Broad data 
Thin margins · 5.0% net margin (TTM) 
Moderate debt 
Mixed vs. peers (7/14) 
Moderate moat 46/100 · thin data
Profit last quarter 47% below a year ago. 
Fair value £1.56 · Strongly overvalued 

Main risks:

🚩Medicare reimbursement changes could cut prices🚩Coloplast and Hollister could take share🚩Patent compensation claim could cost hundreds of millions
Watch ConvaTec Group PLC for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£2.87 £1.50 Fair Value £1.56 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 18, 2026.

How to read this chart

60‑month range £1.50 – £2.87 · fair‑value band £0.9700 – £2.18 · the £2.68 price screens above the £1.56 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 18, 2026.

Follow ConvaTec Group in your weekly email

Every Wednesday you see whether ConvaTec Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Convatec Group PLC engages in the development, manufacturing, and sale of medical products, services and technologies for the management of chronic conditions in Europe, North America, and internationally.

Show moreShow less

The company offers advanced wound care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns.

It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, bladder cancer, inflammatory bowel disease, and trauma.

In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, neurological disease, prostate enlargement or other causes.

Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for use in continuous infusion treatments for conditions such as Parkinson's disease.

The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers.

Convatec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Stock analysis

ConvaTec Group PLC (CTEC) currently trades at £2.68, while our model-based Fair Value estimate is £1.56, 42% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of £1.76 per share, and 2 of the 23 models we run sit above the £2.68 price.

Bear case: the Economic Profit group reads lowest at £0.8550, and 21 of the 23 models stay below the price. Data coverage for this calculation is high.

Scenario range: £0.9700 (bear) to £2.18 (bull), the price of £2.68 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

ConvaTec Group PLC reported revenue of $2.5B in FY2025 versus $2.0B in FY2021, a compound +5.1%/yr. Reported net income was $179M in FY2025, compounding +11.0%/yr from FY2021.

Key figures

Market cap £5.3B Mid · P/E ratio 53.6 · P/S ratio 2.77 · EPS (TTM) £0.0500 · Dividend yield 2.1% · Net margin 5.0% · Return on equity 7.7% · Return on assets (EBIT) 7.7% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 1% below its 52-week high and 39% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −42%, CTEC screens cheaper than that median.

Fair Value models

Bear £0.9700 Fair Value £1.56 Bull £2.18
Price £2.68 · Downside -41.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF £1.11 £1.80 £2.75 79
Growth DCF £1.14 £1.78 £2.61 78
Residual Income £0.5500 £0.6300 £0.7800 76
All 23 models by family
DCF Models
FCF DCF £1.11 £1.80 £2.75 79
Owner Earnings £0.6800 £1.19 £1.89 75
5Y Revenue Exit £0.9700 £1.72 £2.65 71
5Y EBITDA Exit £1.56 £2.78 £4.15 74
5Y P/E Exit £0.7300 £1.29 £1.85 70
10Y Revenue Exit £0.9700 £1.64 £2.47 66
10Y EBITDA Exit £1.37 £2.34 £3.54 67
10Y P/E Exit £0.8600 £1.35 £1.90 64
Earnings-Based
Graham-Dodd £0.4800 £1.19 £1.53 65
PEG = 1.0 £0.5600 £0.8100 £1.05 57
EPV £0.7700 £0.9700 £1.14 74
Dividend Discount
Gordon GGM £0.6200 £1.09 £1.66 67
DDM Multi-Stage £0.6200 £0.9200 £1.22 67
Multiples
P/E Multiple £1.18 £1.57 £1.96 63
P/S Multiple £0.9100 £1.21 £1.51 58
EV/EBIT £1.50 £2.20 £2.91 65
EV/EBITDA £2.08 £2.98 £3.88 67
EV/Revenue £0.8900 £1.54 £2.19 52
Growth DCF
Growth DCF £1.14 £1.78 £2.61 78
Rev-Margin DCF £0.9700 £1.74 £2.58 71
Economic Profit
Residual Income £0.5500 £0.6300 £0.7800 76
ROIC Compounder £0.7900 £1.08 £1.40 72
Growth Earnings
Growth-Adj P/E £0.9000 £1.28 £1.67 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 68/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 47
How much profit the company makes from its sales and capital
Quality Growth 51
Are margins and returns getting better?
Cashflow 73
Do the profits arrive as real cash?
Financial strength 49
Debt, balance sheet and risk of trouble
Investment 91
Does it invest with discipline instead of growing at any price?
Low Volatility 76
How calm the share price moves, does not count
Price momentum 64
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 75
Distance to the 52-week high, does not count
New shares 99
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 70/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+8.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Start year 2020 (pandemic). Over 10 years: +4.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+11.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.4%
Dividend (yield on the price)2.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 17%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +10.0% a year for the price and +2.9% for the forecasts.
Forecast 2026 (sales)+2.6%
Forecast 2027 (sales)+7.0%
Projected 2028 (sales)+6.4%
Projected 2029 (sales)+5.7%
Projected 2030 (sales)+5.1%

CTEC screens overvalued: fair value 42% below the price. Compare with Intuitive Surgical, Inc →

Earlier news

News mood ⓘNews mood, the average tone of recent news (80 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 11, 2026
AI conclusion: Convatec's completed turnaround with faster product launches and higher R&D forms the main strength for organic growth, while thin evidence of a durable moat remains the key weakness against sector peers.
Main risk: US Medicare reimbursement reductions for biologics and potential competitive bidding in continence and ostomy products could lower prices and volumes for affected devices.
Bull case: By accelerating targeted product launches and expanding into less reimbursement-sensitive areas such as infusion sets for new therapies the company could offset pricing pressure and sustain organic growth.
Bear case: Deeper Medicare cuts combined with successful rival encroachment and an adverse ruling in the patent claim could materially reduce revenues, margins and cash flow over several years.
Convatec has completed its multiyear turnaround and its new CEO is accelerating the pace of new product launches while increasing R&D spend to support 6-8% sales growth next year. This comes as the company rolls out innovations like the recent Cure Aqua catheter across categories. Our models currently see the stock as overvalued. Will the faster innovation cycle deliver enough organic growth to justify the premium or will competitive pressures and execution keep margins under pressure?
Join the discussion →

Compare ConvaTec Group PLC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 199 stocks

Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 68 · Top 25%
Fair Value upside −41.8% · Below median
Profitability
Return on equity (12 months) 7.7% · Above median
Return on assets 4.7% · Above median
Net margin (12 months) 5.0% · Below median
Operating margin (12 months) 16.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 4.4% · Below median
Dividend yield (12 months) 2.1% · Above median
Balance sheet
Debt / equity 0.92× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (12 months) 53.6× · Priciest 25%
P/B 4.55× · book value is mostly intangible assets ⓘGoodwill and other intangible assets (such as prices paid for past acquisitions, brands, licences or film and series rights) are larger than the equity. So we do not rank this P/B against the peer group.
P/S (12 months) 2.77× · Pricier than median
Price / free cash flow (fiscal year) 20.2× · Cheaper than median
EV/EBITDA 14.1× · Pricier than median
PEG 0.62× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 24
FUTURE (revenue growth)22 · sector 40
PAST (return on equity)31 · sector 26
HEALTH (low debt)54 · sector 96
DIVIDEND (yield)41 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $86.48 $131.27 +52% vs CTEC
EssilorLuxottica Société anonyme EL €176.80 €196.22 +11% vs CTEC
Intuitive Surgical, Inc ISRG $420.95 $353.90 −16% vs CTEC
Medline Inc MDLN $39.16 $28.59 −27% vs CTEC
Alcon Inc ALC CHF 63.32 CHF 35.08 −45% vs CTEC
Becton, Dickinson and Company BDX $216.08 $97.80 −55% vs CTEC
Straumann Holding STMN CHF 108.60 CHF 45.50 −58% vs CTEC
West Pharmaceutical Services, Inc WST $404.02 $139.22 −66% vs CTEC
Sartorius Stedim Biotech S.A DIM €228.60 €54.82 −76% vs CTEC
Sartorius Aktiengesellschaft SRT €235.50 €46.44 −80% vs CTEC

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ConvaTec Group PLC: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "ConvaTec Group PLC Fair Value". https://www.fairvalue-calculator.com/stock/CTEC

Frequently asked questions

Is ConvaTec Group PLC (CTEC) overvalued or undervalued?
As of Nov 18, 2026, our model estimates a fair value of £1.56 versus a price of £2.68, about 42% lower (overvalued).
What is the fair value of CTEC?
Our model-based fair value for ConvaTec Group PLC is £1.56 (as of Nov 18, 2026), built from audited fundamentals. The current price: £2.68.
What is the quality score of CTEC?
ConvaTec Group PLC has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ConvaTec Group PLC (CTEC)?
We do not set a price target; the yardstick is the fair value of £1.56 (as of Nov 18, 2026) from 23 valuation models. Cautious scenario £0.9700, optimistic scenario £2.18. It is a calculation from audited fundamentals, not an analyst target.
What is the ConvaTec Group PLC stock forecast for 2026?
Our models put fair value at £1.56, about 42% lower versus a price of £2.68 (overvalued). Cautious scenario £0.9700, optimistic scenario £2.18. The calculation is refreshed regularly with new filings.
What is the revenue of ConvaTec Group PLC (CTEC)?
ConvaTec Group PLC reported trailing-twelve-month revenue of about $2.5B (latest available figure, as of Nov 18, 2026).
Does ConvaTec Group PLC pay a dividend?
ConvaTec Group PLC currently shows a dividend yield of 2.07% relative to its recent price (as of Nov 18, 2026).
How much is the dividend of ConvaTec Group PLC (CTEC) and when is the ex-dividend date?
ConvaTec Group PLC pays a dividend of £0.0555 per share a year, a dividend yield of 2.1%. The last ex-dividend date was Aug 20, 2026. A dividend has been paid every year since at least 2017. The payout ratio is 77.8% of earnings. Free cash flow covers the dividend 2.46 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into ConvaTec Group PLC (CTEC)?
For today's price to be fair in a discounted-cash-flow model, ConvaTec Group PLC would have to grow free cash flow by 12.6 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 5.6 % per year. As of Nov 18, 2026.
What discount rate (WACC) does the fair value of CTEC use?
Our models discount ConvaTec Group PLC at 9.6 %: a base by market capitalisation (mid), damped by beta 0.73, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For ConvaTec Group PLC that is +12.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has ConvaTec Group PLC (CTEC) delivered so far?
Over the past 5 years revenue at ConvaTec Group PLC grew 5.6 % a year. The price currently implies free-cash-flow growth of +12.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of ConvaTec Group PLC (CTEC) growing?
The median revenue growth in the sector is +7.4 % a year. That is the yardstick for the growth priced into ConvaTec Group PLC (+12.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of ConvaTec Group PLC (CTEC)?
The free-cash-flow yield on the price is 4.95 %: that much free cash flow ConvaTec Group PLC produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of ConvaTec Group PLC (CTEC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ConvaTec Group PLC it is £1.56 per share (as of Nov 18, 2026), against a price of £2.68. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is ConvaTec Group PLC stock overvalued or undervalued in 2026?
As of Nov 18, 2026, CTEC trades above its calculated fair value: price £2.68, fair value £1.56, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CTEC?
No. The price is what the market pays today (£2.68); the fair value is what the company's own numbers justify (£1.56). For ConvaTec Group PLC the two are £1.12 per share apart. That gap is exactly why we show both numbers side by side.
How much is ConvaTec Group PLC worth?
The market values ConvaTec Group PLC at about £5.3B (market capitalisation, as of Nov 18, 2026). Per share that is £2.68; our models calculate a fair value of £1.56 per share.
What do the bullish and bearish scenarios say about CTEC?
Our models span a range for ConvaTec Group PLC: cautious scenario £0.9700, base £1.56, optimistic £2.18 per share (as of Nov 18, 2026, price £2.68). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CTEC?
ConvaTec Group PLC trades at a price-to-earnings ratio of 53.6 (as of Nov 18, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of £1.56 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2025), reported earnings: 45.0. Other multiples: PEG 0.6, P/B 4.6, P/S 2.8, EV/EBITDA 14.1.
What is the PEG ratio of CTEC?
The PEG ratio of ConvaTec Group PLC is 0.62 (P/E divided by earnings growth, as of Nov 18, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of ConvaTec Group PLC (CTEC)?
Balance-sheet figures for ConvaTec Group PLC (as of Nov 18, 2026): return on equity 7.7%, debt of 0.92 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is CTEC from its 52-week high?
ConvaTec Group PLC trades at £2.68, about 1% below its 52-week high of £2.70 and 39% above the low of £1.93 (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of £1.56 is for.
Which stocks are comparable to ConvaTec Group PLC?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ConvaTec Group PLC stock attractive at the current price?
The data as of Nov 18, 2026: price £2.68, calculated fair value £1.56 (−42%), Quality Score 68/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CTEC calculated?
We run ConvaTec Group PLC through 23 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of £1.56 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. ConvaTec Group PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ConvaTec Group PLC (CTEC)?
The closing price on Nov 19, 2026 was £2.68. Our model-based fair value is £1.56, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ConvaTec Group PLC right now?
The price sits above even our optimistic bull case (£2.18). The favourable scenario is already priced in. Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (£0.9700 to £2.18) leaves room in how you read the outcome.

Key figures of ConvaTec Group PLC

How large is the market capitalisation of ConvaTec Group PLC (CTEC)?
The market capitalisation of ConvaTec Group PLC is £5.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ConvaTec Group PLC (CTEC)?
The price-to-sales ratio of ConvaTec Group PLC is 2.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of ConvaTec Group PLC (CTEC)?
Earnings per share at ConvaTec Group PLC are £0.0500 (price ÷ EPS = P/E 53.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of ConvaTec Group PLC (CTEC)?
The dividend yield of ConvaTec Group PLC is 2.1% (payout 111%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of ConvaTec Group PLC (CTEC)?
The net margin of ConvaTec Group PLC is 5.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ConvaTec Group PLC (CTEC)?
The return on equity (ROE) of ConvaTec Group PLC is 7.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ConvaTec Group PLC (CTEC)?
On an EBIT basis the return on assets of ConvaTec Group PLC is 7.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ConvaTec Group PLC (CTEC)?
The operating margin of ConvaTec Group PLC is 16.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ConvaTec Group PLC (CTEC)?
Revenue at ConvaTec Group PLC is growing 4.4% versus a year earlier (3y avg +6.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at ConvaTec Group PLC (CTEC)?
Earnings per share at ConvaTec Group PLC are down 47.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does ConvaTec Group PLC (CTEC) carry?
The net debt of ConvaTec Group PLC is $1.5B (fiscal year 2025, ≈ 4.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch ConvaTec Group PLC in the live analysis

One click puts ConvaTec Group PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.